EUVIMEDEUVIMED entdecken
Crossref

Combination Therapy Against Breast Cancer Cells by Docetaxel With Rosmarinic and Thymoquinone: An Experimental Study

Ebrahim Afkhami Saray, Sodeif Azadmard-Damirchi, Mahdi Gharekhani

Crescent Journal of Medical and Biological Sciences · 2022

DOI: 10.34172/cjmb.2022.11 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Crescent Journal of Medical and Biological Sciences, 2022. Verfasst von Ebrahim Afkhami Saray und 2 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Combination therapy with powerful and new components is presented as an effective method in treating breast cancer against conventional approaches. Here, we tried to evaluate the implementation of rosmarinic and thymoquinone on the tumor growth inhibition and apoptotic induction of docetaxel on MDA-MB231 breast cancer cells. Materials and Methods: The drug interaction between rosmarinic acid, thymoquinone, and docetaxel, as the chemotherapeutic drug, was analyzed using the Chou-Talalay method along with CompuSyn. To understand the number of cell proliferation of MDA-MB231 breast cancer, a tetrazolium-based colorimetric assay (MTT assay) was investigated. DAPI and the flowcytometric assay were harnessed to evaluate the morphology and the percentage of apoptosis, respectively. Real-time polymerase chain reaction (PCR) was used to recognize the association between the NF-κB pathway and program cell death signal.

Results

The IC50 values for docetaxel, rosmarinic, and Thymoquinone were 2.6 ± 0.62 nM, 15.6 ± 2.4 µM, and 35.5 ± 3.4 μM, respectively. MDA-MB231 breast cancer showed combination index value following three combination recipes; rosmarinic acid + docetaxel, thymoquinone + docetaxel, rosmarinic acid + thymoquinone + docetaxel was 0.26, 0.55, and 0.08, which designated a remarkable synergistic effect. The cultivation of the tumor cells under the exposition of docetaxel and rosmarinic, as well as thymoquinone, discovered a substantial upsurge in the anti-proliferative manner of docetaxel from 60% to 82%, along with a double-fold surge in the number of dead cells. mRNA levels exhibited a noticeable decline in IκB-α as an indicator of NF-κB activation and the decline of survivin and Bcl-2 escorted by a surge in pro-apoptotic Bad mRNA levels (P

Zitieren

APA

Saray, E. A., Azadmard-Damirchi, S., & Gharekhani, M. (2022). Combination Therapy Against Breast Cancer Cells by Docetaxel With Rosmarinic and Thymoquinone: An Experimental Study. Crescent Journal of Medical and Biological Sciences. https://doi.org/10.34172/cjmb.2022.11

Vancouver

Saray EA, Azadmard-Damirchi S, Gharekhani M. Combination Therapy Against Breast Cancer Cells by Docetaxel With Rosmarinic and Thymoquinone: An Experimental Study. Crescent Journal of Medical and Biological Sciences. 2022. doi:10.34172/cjmb.2022.11

BibTeX
@article{Saray2022,
  author = {Saray, Ebrahim Afkhami and Azadmard-Damirchi, Sodeif and Gharekhani, Mahdi},
  title = {Combination Therapy Against Breast Cancer Cells by Docetaxel With Rosmarinic and Thymoquinone: An Experimental Study},
  journal = {Crescent Journal of Medical and Biological Sciences},
  year = {2022},
  doi = {10.34172/cjmb.2022.11}
}
Kostenlos starten →